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Abstract Five percent of patients on dual antiplatelet
therapy after coronary artery stent implantation will need
non-cardiac surgery within the first year of therapy, and
many more will need surgery later on. A function assay that
evaluates platelet reactivity and inhibition by drug therapy is
beneficial for such patients. Platelet Mapping assay (PMTM)
using the TEG analyzer was tested in surgical patients.
After IRB approval, 60 patients on combined aspirin and
clopidogrel therapy were consented and enrolled. The TEG
maximal amplitude (MA) and the percentage (%) platelet
inhibition were recorded and analyzed. Fifty-seven patients
(mean age 65.7 ± 10.9 years) had preoperative data only.
Distribution of preoperative ADP (43.6 ± 24.4 %) and AA
inhibition (52.8 ± 30.2 %) was determined, as well as for
the preoperative MA ADP (43.1 ± 15.9 mm) and MA AA
(37.2 ± 19.6 mm), showing an offset of the effect of both
medications starting from day 3. Patients with complete pre-
and postoperative data were stratified depending on duration
off antiplatelet therapy (B3 days, 3–7 days and [7 days):
n = 27, ADP % preop inhibition (43.2 ± 21.6 %), ADP %
postop inhibition (32.3 ± 18.3 %), p = 0.048. Distribution
of immediate pre- and post- ADP and AA % inhibitions,
showing a possible reduction in D of inhibition for clopi-
dogrel at 3 days, were also assessed. Conclusion: According
to the findings, the TEG PMTM assay might be a feasible
approach to objectively evaluate the effects of aspirin and
clopidogrel during the perioperative period and potentially
guide drug management.
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Introduction
Coronary artery disease is the largest cause of mortality in
the USA, accounting for 32.8 % of deaths in the country
[1]. Percutaneous coronary intervention (PCI) and coronary
artery stenting are mainstays of treating this serious con-
dition, and dual antiplatelet therapy (DAPT) consisting of
aspirin (ASA) and clopidogrel in coronary artery disease
(CAD) patients needs to be continued for at least
12 months in patients with drug eluting stents presenting
for non-cardiac surgery (NCS) [2]. About 5 % of these
patients will present during the first year of implantation,
but many more may need surgery after that. Most proce-
dures will be of a non-cardiac nature and, besides original
evidence that 12 months is safer, a conflicting concern is
that, even after 12 months, the risk may not be as low as
expected. With single antiplatelet therapy increasing the
risk of surgical hemorrhage to 20 % and DAPT increasing
it to 50 %, the assessment of platelet function in these
patients for guiding appropriate DAPT management pre-,
peri- and postoperatively has become essential [3].
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Current American Heart Association and College of
Cardiology guidelines recommend that DAPT be continued
for 12 months, ASA be continued during NCS surgery, and
clopidogrel be stopped 5–7 days before NCS (if requested
by surgeon, ASA may also be stopped 7–10 days before
NCS) [4, 5]. However, it has been demonstrated that not all
patients respond similarly to antiplatelet therapy [6]. The
risk of excessive intraoperative bleeding must therefore be
carefully balanced against the increased risk that discon-
tinuing antiplatelet therapy before NCS has on myocardial
infarction and stroke [7]. Simple and rapid methodologies
to evaluate platelet function in treated patients might be
useful for clinical practice. The TEG (Haemonetics, Brain
Tree, MA, USA) is an example of one such platelet func-
tion analyzer; now that it has the added technology of
Platelet Mapping assay (TEG PMTM), it is of even more
value in measuring the hemostatic function of patients.
The aims of this pilot observational study were to: (1)
assess patients’ preoperative platelet function based on days
off of antiplatelet therapy, and (2) evaluate changes in
platelet function after NCS. Our original hypothesis set forth
that (a) preoperative platelet inhibition would be lower than
expected (\90 % population) at the time of preoperative
assessment and (b) the postoperative inhibition for patients
with preoperative values between 50 and 75 % would
change to a lower value postoperatively. The hypothesis was
based on the effect of drug pharmocogenetics, pharmaco-
kinetics, and surgical stress induced prothrombosis.
Methods
After approval from the Committee for the Protection of
Human Subjects (CPHS), 60 adult patients who were receiv-
ing or had recently suspended combined aspirin and clopi-
dogrel therapy due to either coronary stent implantation or
grafting were enrolled. Exclusionary criteria included any
anticoagulatory medication other than aspirin and clopido-
grel, end-stage renal failure, liver disease with recognized
coagulopathy, or recent utilization of nonsteroidal anti-
inflammatory drugs (NSAIDs). All patients gave their written
informed consent and were surgical candidates scheduled for
an elective operative procedure who presented to either the
preoperative anesthesia clinic or the day surgery area. Subjects
were questioned on reasons for surgical procedure, duration of
antiplatelet therapy, and timing of the last dose of aspirin and
clopidogrel. Patient demographics, current medications, and
surgical procedures have been reported in Table 1.
Blood sampling
Baseline blood samples were drawn in the preoperative
anesthesia clinic on the day of anesthesiological examination
or in the day-surgery area on the day of surgery for those
patients not presenting to the preoperative anesthesia clinic
(Fig. 1). Postoperatively, blood samples were obtained the
day of surgery in the peri-anesthesia care unit (PACU) from 27
patients on clopidogrel therapy (clopidogrel group) and from
28 patients on aspirin therapy (aspirin group). Per standard
practice to avoid shear activation, blood samples for the TEG
PMTM were drawn from a single clean puncture of a forearm
vein in the preoperative anesthesia clinic after routine blood
for routine surgical work-up was drawn, or from an already
placed intravenous line in the day surgery and PACU units.
Blood (3–4 mL) was collected in a 4.0 mL test tube con-
taining lithium heparin 14.5 U mL-1 (VacuetteTM) and
whole fresh blood (2 mL) in a 3 mL regular syringe.
Table 1 General demographics, length of aspirin/clopidogrel
suspension, and TEG PMTM values
Gender
Male n = 30 (53 %)
Female n = 27 (47 %)
Surgical procedures
Neuro/ortho 20 (35 %)
General surgery 16 (28 %)
ENT 10 (17 %)
Urology 6 (11 %)
Others 5 (9 %)
Mean ± SD Median 25–75
Interquartile
Age 65.7 ± 10.9 67.0 60.0–71.0
Days off of clopidogrel 5.3 ± 8.8 4.0 1.0–7.0
Days off of aspirin 3.1 ± 4.9 1.0 0.0–4.0
Baseline SP (min) 5.7 ± 2.5 5.7 4.4–6.9
Baseline R (min) 7.0 ± 2.7 6.8 5.5–8.2
Baseline K (min) 2.3 ± 0.9 2.2 1.8–2.6
Baseline Angle (degrees) 60.0 ± 9.0 60.3 54.9–65.0
Baseline MA (mm) 68.8 ± 5.1 68.7 65.1–72.4
Preop-ADP (n = 57)
MA (mm) 43.1 ± 15.9 45.2 32.9–56.0
% Inhibition (%) 43.6 ± 24.4 42.8 24.8–59.6
Preop-AA (n = 57)
MA (mm) 37.2 ± 19.6 40.3 18.5–52.9
% Inhibition (%) 52.8 ± 30.2 52.1 26.1–74.7
Postop-ADP (n = 27)
MA (mm) 49.3 ± 13.1 50.0 43.0–55.5
% Inhibition (%) 30.7 ± 18.6 27.2 17.9–39.9
Postop-AA (n = 29)
MA (mm) 43.1 ± 18.9 47.1 33.5–52.5
% Inhibition (%) 45.0 ± 33.4 35.2 19.2–68.8
SD standard deviation; SP split point; MA maximal amplitude; ADP
adenosine diphosphate; AA arachidonic acid; R and K are standard
TEG parameters
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Measurements
In order to monitor platelet function, blood was immedi-
ately processed at the point-of-care and analyzed by using
the TEG analyzer. The following parameters were mea-
sured and graphically displayed: (1) the R value (Reaction
time), i.e. the time from the start of a sample run until the
first significant levels of detectable clot formation; (2) the
K value (K Time), i.e. the time from the end of R time until
the level of clot strength reaches an amplitude of 20 mm,
representative of the speed of clot kinetics; (3) a angle,
i.e. the measure of the acceleration of fibrin build-up and
cross-linking (clot strengthening); (4) the SP value (Split
Point), i.e. the time to initial amplitude when the tracing
starts to split, indicating clotting; and (5) the maximal
amplitude (MA), a direct function of the maximum clot
strength [8].
The TEG PMTM gives quantitative analysis of platelet
function based on the formation, strength, and degradation of
clots in whole blood. Maximal clot strength (MAThrombin) is
the maximum amplitude and was achieved by transferring
1 mL of whole blood to a vial containing kaolin which was
then mixed by inversion. The kaolin activated blood
(360 lL) was transferred to the first TEG cup as a standard
TEG. In order to detect the fibrin contribution to clot
strength, blood (360 lL) from the heparinized tube was
transferred to the second TEG cup containing 10 lL
Activator F, a mixture of reptilase and factor XIII, (MAFibrin).
The P2Y12 receptor contribution to clot formation was
assessed by the addition of 360 lL heparinized blood to the
third TEG cup along with 10 ll of 2 lM ADP (MAADP) and
10 lL Activator F. Likewise, the contribution of the COX-1
pathway to clot formation was assessed by transferring
360 lL heparinized blood to 10 lL of 1 mM AA (MAAA) and
10 lL Activator F to the fourth TEG cup. The addition of
exogenous ADP and AA allows determination of the response
of the ADP and thromboxane A2 (TXA2) receptors, respec-
tively. The percentage platelet aggregation to agonist can be
calculated by: [(MAADP/AA - MAFibrin)/(MAThrombin -
MAFibrin) 9 100] and is calculated by the TEG
 PMTM
software. The raw MA data from the TEG PMTM and per-
centage platelet inhibition were assessed and recorded.
The reference ranges for the kaolin TEG parameters
were R = 4–8 min, K = 0–4 min, a = 47-74, and MA =
54–72 mm. For the TEG PMTM, an MA greater than 50
was considered normal for both AA and ADP, as well as an
Enrolled (n=60)
Excluded (n=3) due to 
improper TEG® PM™ 
sampling technique
Clinic with DOS Preop 
(n=5)
Clinic Preop Only 
(n=10)
DOS Preop Only 
(n=13)
Clinic with DOS Preop and Postop 
(n=7)
DOS Preopand Postop 
(n=22)
Analyzed (n=57)
DOS = Day of Surgery
Fig. 1 This CONSORT flow
diagram illustrates the
enrollment and sample
collection of patients involved
in the study. DOS day of surgery
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inhibition less than 30 % for aspirin (AA) and clopidogrel
(ADP) [10, 11]. However, an interindividual variability is
recognized especially for ADP, setting values of inhibition
for ADP up to 40 % as normal [9, 10].
Statistical analysis
In this pilot, observational study, the results were ana-
lyzed utilizing STATA (STATA Corp., Version 10.0,
College Station, TX). The outcome variables were pre-
sented as mean ± standard deviations, as well as the
median and the 1st and 3rd quartiles. Preoperative and
postoperative data were stratified per duration of therapy
suspension (B3, 3–7 and [7 days). Robust locally
weighted polynomial regression was used to create a best
fit on all patients based on the days off antiplatelet
therapy. Comparison and p value was calculated from
non-parametric Wilcoxon rank sum test. A p value \0.05
was considered significant.
Results
Demographics and laboratory data are presented in
Table 1. Three subjects were excluded from analysis
because of improper handling of samples or missing val-
ues precluding analysis. Average interruption was 5.3 ±
8.8 days for clopidogrel and 3.1 ± 4.9 days for aspirin.
Preoperative baseline MA values were similar in both the
clopidogrel and aspirin groups. Patients were distributed on
a scatter plot depending on the duration off antiplatelet
therapy (Figs. 2, 3). The mean and corresponding 25–75
interquartile for each day off antiplatelet therapy are also
displayed for both the clopidogrel and aspirin groups.
Combined preoperative and postoperative data was
available on 27 of the 57 patients who were receiving or
had recently suspended clopidogrel (Table 2). These
patients were divided into 3 groups, depending on the
duration off clopidogrel (B3, 3–7, and[7 days). Although
all 3 groups showed decreased % inhibition in the
postoperative samples, the only statistical significance
(p \ 0.048) was found when combining all the 3 groups
together. These same patients were then distributed on a
box-and-whisker plot with both their preoperative and
postoperative values for comparison (Fig. 4). A difference
seems to be noted on the plot for patients off clopidogrel
B5 days, which is consistent with the grouping of the
patients into two groups (0 B 5 and [5 days) (Table 2),
where a statistical difference (p \ 0.02) was observed in
the patients off clopidogrel from the 0 B 5 days group.
Preoperative and postoperative data were available on
29 of the 57 patients who were currently on or had recently
suspended aspirin, similarly divided into 3 groups this time
depending on suspension of aspirin (B3, 3–7, and[7 days)
(Table 3). Distribution of preoperative to postoperative AA
% inhibition showed similar patterns of decreasing inhi-
bition with interruption of aspirin but did not reach sig-
nificance (Fig. 5).
Fig. 2 The a preoperative MA
ADP and b preoperative ADP %
inhibition in the 57 patients are
distributed on a scatter plot
depending on the duration off
clopidogrel. The median and
corresponding 25–75
interquartiles for each day off
clopidogrel are also displayed.
MA maximum amplitude; ADP
adenosine diphosphate. Test
performed either in
preanesthesia clinic or in day-
surgery unit on day-of-surgery.
The solid line represents the cut-
off for normality
(MA = 50 mm;
% inhibition = 45)
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Discussion
This study has demonstrated that patients receiving or
having recently suspended dual antiplatelet therapy (DAPT)
presenting for non-cardiac surgery (NCS) at the anesthesia
preoperative clinic or on the day of surgery have higher
levels of preoperative platelet inhibition with respect to
those patients that interrupted antiplatelet therapy most
recently. A sequential decline that parallels longer inter-
ruption of clopidogrel or aspirin therapy was noted. This
trend supports recent findings by Collyer et al. [9] and
highlights the need for objective recommendations to guide
decisions as to how long to safely suspend antiplatelet
therapy prior to surgery. In addition, a trend to decreased
platelet inhibition in postoperative samples especially for
patients taking clopidogrel, although this did not reach
significance, was noted. This may be related to effects of
surgery on platelet reactivity, increased platelet aggrega-
bility [12] and increased activation of the sympatho-adrenal
axis and catecholamine release [13]. By utilizing a patient
population on combined antiplatelet therapy, this study
distinguishes itself from previously published studies on the
effects of antiplatelet therapy on platelet inhibition. Our
findings are of more value to practitioners, who must fre-
quently treat patients on DAPT in the clinical setting.
Timing of elective surgery is a major concern in patients
with coronary artery stents who are receiving antiplatelet
therapy. Low levels of preoperative platelet inhibition
may be related to incomplete responsiveness to clopidogrel
and/or aspirin therapy, an increasingly recognized concern
Table 2 Preoperative and postoperative percent (%) platelet inhibition in 27 patients separated into 3 groups by days off of clopidogrel (0 B 3,
3 B 7 and [7 days) and into 2 groups by days off of clopidogrel (0 B 5 and [5 days)
Days off of clopidogrel N ADP % preop inhibition ADP % postop inhibition p value
Mean Median Mean Median
0 B 3 days 11 51.9 ± 24.6 56 (33.7, 62.65) 37.6 ± 24.6 38.4 (18.5, 48.5) 0.13
3 B 7 days 11 39.5 ± 20 41.6 (22.15, 53.3) 29.2 ± 9.8 33.5 (21.9, 36.1) 0.25
[7 days 5 32.1 ± 10.3 29.4 (23.9, 38.8) 27.7 ± 17 27.2 (24.8, 38.6) 0.84
Total patients 27 43.2 ± 21.6 41.6 (25.6, 58.8) 32.3 ± 18.3 33.5 (21.25, 40.8) 0.048*
0 B 5 days 17 51.3 ± 21.2 49.3 (41.5, 61.4) 35.5 ± 20.6 35.9 (21, 45) 0.02*
[5 days 10 29.5 ± 14.7 25.2 (19, 36.5) 27 ± 12.6 26 (21.7, 35.6) 0.99
Data are presented as mean ± SD and median (1st and 3rd quartile). p value was calculated from non-parametric Wilcoxon rank sum test.
SD standard deviation; ADP adenosine diphosphate
Fig. 3 The a preoperative MA
AA and b preoperative AA %
inhibition in the 57 patients are
distributed on a scatter plot
depending on the duration off
aspirin. The median and
corresponding 25-75
interquartiles for each day off
aspirin are also displayed. MA
maximum amplitude; AA
arachidonic acid. Test
performed in PACU after
anesthesia team handed patient
off to nursing staff. The solid
line represents the cut-off for
normality (MA = 50 mm;
% inhibition = 45)
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[13, 14]. Preisman et al. [15] comment on this lack of
patient responsiveness to therapy by stressing the impor-
tance of measuring platelet function in patients undergoing
cardio-thoracic surgery. We used prospective data from
this present study to reiterate the need to measure platelet
function in all patients on antiplatelet therapy [16].
A recent modification of the TEG analysis that includes
Platelet MappingTM assay has generated interest. This assay
facilitates not only the evaluation of the activation of
arachidonic acid (AA) and adenosine diphosphate (ADP)
pathways, allowing evaluation of the potential inhibition
of those pathways by aspirin and clopidogrel, respectively
[17, 18], but it may also permit assessment of the clotting
status for the exclusion of a possible haemostasis imbalance
toward a hemorrhagic status. The immediate availability of
assessment of platelet function by point-of-care methodol-
ogy may provide objective evidence of platelet inhibition
and aid physician judgment in appropriate interruption of
antiplatelet therapy for surgical procedures, facilitating per-
sonalized, data-driven management of antiplatelet therapy.
An important consideration is worth mentioning. While
meaningful results have been seen in studies that document
agreement between TEG PMTM and platelet responsive-
ness due to thromboxane [19], inconsistencies have also
been noticed between the ADP or the AA pathways mea-
sured by different point-of-care devices and compared to
light aggregonometry [20]. Breet et al. [21] compared the
predictive power of several well-known platelet function
tests (the VerifyNow P2Y12 and PlateletWorks assays, and
the IMPACT-R and the platelet function system [PFA-
100]), with the exception of the TEG PMTM, and con-
cluded all tests had about a 60 % sensitivity and 60 %
specificity. Concerns about the low sensitivity of the TEG
PMTM stem from initial results by Tantry et al. [20];
however, Collyer et al. [9] and Bochsen et al. [10] have
retested the TEG and TEG PMTM assays and found
Fig. 4 Whisker plot distribution comparing preoperative and post-
operative percent (%) inhibition in 27 patients based on days off
clopidogrel. Preoperative values are expressed in green while
postoperative values are expressed in orange
Table 3 Preoperative and postoperative percent (%) platelet inhibition (mean ± SD) in 29 patients separated into 3 groups by their days off of
aspirin (0 B 3, 3 B 7 and [7 days)
Days off of aspirin N AA % preop inhibition AA % postop inhibition p value
Mean Median Mean Median
0 B 3 days 18 58.7 ± 31.3 63.1 (31.5, 85.8) 50.2 ± 30 47.8 (28.8, 76.6) 0.44
3 B 7 days 7 47.8 ± 28.1 43.1 (27.9, 63.4) 50.6 ± 41.8 62.3 (13.3, 83) 0.9
[7 days 4 17.9 ± 6.8 20 (16.8, 21.2) 11.5 ± 9.6 12.3 (5,7, 18.2) 0.34
Total patients 29 50.5 ± 31.1 42.5 (23.1, 72.4) 45 ± 33.4 35.2 (19.2, 68.8) 0.43
Data are presented as mean ± SD and median (1st and 3rd quartile). p value was calculated from non-parametric Wilcoxon rank sum test.
SD standard deviation; AA arachidonic acid
Fig. 5 Whisker plot distribution comparing preoperative and post-
operative percent (%) inhibition in 29 patients based on days off
aspirin. Preoperative values are expressed in green while postoper-
ative values are expressed in orange
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them to be adequate in their sensitivity to platelet function.
Indeed, the variability of reported TEG PMTM data is in
agreement with that showed by Collyer et al. [9]. This
extreme variability in patient inhibition levels may be
unrelated to antiplatelet therapy, due instead to different
intrinsic patient factors (i.e. genetic polymorphisms, dif-
ferent TxA2 or ADP receptor concentrations used, or the
type of testing used [10]).
However a body of evidence indicates that cut off points
to define effectiveness or ‘‘resistance’’ to one drug or the
other may have been insufficiently investigated [9, 10].
Indeed, Madsen et al. [20] state ‘‘the effects of aspirin and
clopidogrel on platelet function are not measured routinely,
and no consensus has been reached regarding which lab-
oratory criteria are the most clinically relevant to describe
ALR [aspirin low response] and CLR [clopidogrel low
response]’’. Our understanding of what cut-off values are
appropriate has changed over the years. Originally, Tantry
et al. [11] and Bochsen et al. [10] showed that values of MA
\40 mm or % inhibition [50 % could have been consid-
ered as cut-off values for normal inhibition levels. How-
ever, Collyer et al. [9], Preisman et al. [15], and Mahla
et al. [22] later showed how cut-off values are different
depending on the drug used (aspirin vs. Clopidogrel),
cross-over inhibition, time from suspension of medica-
tion(s), type of surgery, expected complication rate, and
acceptable blood losses. Based on more complex or simple
surgeries, we may want to reconsider the definition of what
constitutes appropriate cut-off values. More investigation is
necessary on this point.
Our preliminary data, together with others [9, 10], suggest
that preoperative assessment of the antiplatelet effects of
aspirin and clopidogrel is not only feasible but also neces-
sary as the baseline level of inhibition (AA and ADP) was
surprisingly low and decreased with longer interruption of
therapy. This finding would support the rationale in main-
taining aspirin therapy perioperatively. If these data are
validated, it may lead to critical re-evaluation of the tradi-
tionally recommended continuation of aspirin and 5–7 days
interruption for clopidogrel. Patients may be exposed to
unnecessary risks of stent thrombosis if waning anti-platelet
effects are demonstrated over a shorter period. This is of
even greater significance given the subsequent additional
decrease in platelet inhibition in postoperative samples,
which coincides with the reported increased incidence of
thrombotic events.
One potential limitation of this study is the use of
patients receiving combined antiplatelet therapy of aspirin
and clopidogrel, making it difficult to discriminate which
effects are caused by which drug. However, dual therapy
can be seen as providing the proper clinical context needed
to evaluate the data. Patients frequently present on DAPT
with aspirin and clopidogrel to treat cardiovascular disease,
making studies like this one valuable to clinicians encoun-
tering such patients.
We recognize that another limitation to this study is the
inconsistent availability either of platelet counts or of
coagulation tests (PT, PTT, INR) in our patient population.
However, a baseline kaolin TEG was recorded for each
patient and was considered a comprehensive test for the
purposes of this study. Due to the varied surgical proce-
dures undergone by the patients enrolled, only the general
surgical area was included in Table 1. This lack of detailed
reporting does pose a limitation as surgical procedures
varied in duration and severity, which may have affected
the results. Additionally, the variability of results produced
by the TEG makes determination of a normal range of
inhibition difficult. Further research is needed to correlate
the measured levels with outcomes, such as cardiac events
during the perioperative period.
In conclusion, we documented low levels of preopera-
tive platelet inhibition, suggesting that use of point-of-care
platelet function testing may be a feasible and logical
approach to objective evaluation of the effects of aspirin
and clopidogrel on the AA and ADP pathways. Validation
of these results in a larger prospective evaluation will likely
provide evidence to guide physicians in the appropriate and
personalized management of DAPT and potential inter-
ruption for elective surgical procedures.
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